Clinical Characteristics and Humoral Responses Related to the Adequate Cell-Mediated Immune Response for Both CD4+ and CD8+ T Cells
| Characteristic . | Adequate CMI Response (n = 8) . | Inadequate CMI Response (n = 32) . | P Value . |
|---|---|---|---|
| Male sex | 0 (0) | 11 (34.4) | .080 |
| Age, y, mean ± SD | 67.5 ± 4.5 | 60.9 ± 9.6 | .070 |
| Age >60 y | 7 (87.5) | 17 (53.1) | .114 |
| ICI (vs cytotoxic chemotherapy) | 6 (75.0) | 5 (15.6) | .003 |
| ECOG performance status grade 0 | 6 (75.0) | 28 (87.5) | .580 |
| Comorbidity | |||
| Hypertension | 2 (25.0) | 6 (18.8) | .650 |
| Diabetes | 2 (25.0) | 6 (18.8) | .650 |
| Lung cancer | 6 (75.0) | 12 (37.5) | .110 |
| Purpose of chemotherapy | .420 | ||
| Palliative | 7 (87.5) | 19 (59.4) | |
| Adjuvant | 1 (12.5) | 5 (15.6) | |
| Curative | 0 (0) | 5 (15.6) | |
| Neoadjuvant | 0 (0) | 3 (9.4) | |
| Cycle of current chemotherapy, median (IQR) | 17 (4–28) | 4 (3–6) | .028 |
| Previous influenza vaccination | |||
| Previous year (2017–2018 vaccine) | 5 (62.5) | 7 (21.9) | .039 |
| Within 3 y | 5 (62.5) | 7 (21.9) | .039 |
| Seroprotection | |||
| H1N1 | 7 (87.5) | 20 (62.5) | .236 |
| H3N2 | 7 (87.5) | 18 (56.3) | .219 |
| No. of seroprotective strains, median (IQR) | 4 (2–4) | 2 (1–4) | .138 |
| Seroconversion | |||
| H1N1 | 5 (62.5) | 14 (43.8) | .442 |
| H3N2 | 3 (37.5) | 12 (37.5) | 1.000 |
| No. of seroconverted strains, median (IQR) | 3 (0–4) | 1 (0–4) | .366 |
| Characteristic . | Adequate CMI Response (n = 8) . | Inadequate CMI Response (n = 32) . | P Value . |
|---|---|---|---|
| Male sex | 0 (0) | 11 (34.4) | .080 |
| Age, y, mean ± SD | 67.5 ± 4.5 | 60.9 ± 9.6 | .070 |
| Age >60 y | 7 (87.5) | 17 (53.1) | .114 |
| ICI (vs cytotoxic chemotherapy) | 6 (75.0) | 5 (15.6) | .003 |
| ECOG performance status grade 0 | 6 (75.0) | 28 (87.5) | .580 |
| Comorbidity | |||
| Hypertension | 2 (25.0) | 6 (18.8) | .650 |
| Diabetes | 2 (25.0) | 6 (18.8) | .650 |
| Lung cancer | 6 (75.0) | 12 (37.5) | .110 |
| Purpose of chemotherapy | .420 | ||
| Palliative | 7 (87.5) | 19 (59.4) | |
| Adjuvant | 1 (12.5) | 5 (15.6) | |
| Curative | 0 (0) | 5 (15.6) | |
| Neoadjuvant | 0 (0) | 3 (9.4) | |
| Cycle of current chemotherapy, median (IQR) | 17 (4–28) | 4 (3–6) | .028 |
| Previous influenza vaccination | |||
| Previous year (2017–2018 vaccine) | 5 (62.5) | 7 (21.9) | .039 |
| Within 3 y | 5 (62.5) | 7 (21.9) | .039 |
| Seroprotection | |||
| H1N1 | 7 (87.5) | 20 (62.5) | .236 |
| H3N2 | 7 (87.5) | 18 (56.3) | .219 |
| No. of seroprotective strains, median (IQR) | 4 (2–4) | 2 (1–4) | .138 |
| Seroconversion | |||
| H1N1 | 5 (62.5) | 14 (43.8) | .442 |
| H3N2 | 3 (37.5) | 12 (37.5) | 1.000 |
| No. of seroconverted strains, median (IQR) | 3 (0–4) | 1 (0–4) | .366 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CMI, cell-mediated immune; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; IQR, interquartile range; SD, standard deviation.
Clinical Characteristics and Humoral Responses Related to the Adequate Cell-Mediated Immune Response for Both CD4+ and CD8+ T Cells
| Characteristic . | Adequate CMI Response (n = 8) . | Inadequate CMI Response (n = 32) . | P Value . |
|---|---|---|---|
| Male sex | 0 (0) | 11 (34.4) | .080 |
| Age, y, mean ± SD | 67.5 ± 4.5 | 60.9 ± 9.6 | .070 |
| Age >60 y | 7 (87.5) | 17 (53.1) | .114 |
| ICI (vs cytotoxic chemotherapy) | 6 (75.0) | 5 (15.6) | .003 |
| ECOG performance status grade 0 | 6 (75.0) | 28 (87.5) | .580 |
| Comorbidity | |||
| Hypertension | 2 (25.0) | 6 (18.8) | .650 |
| Diabetes | 2 (25.0) | 6 (18.8) | .650 |
| Lung cancer | 6 (75.0) | 12 (37.5) | .110 |
| Purpose of chemotherapy | .420 | ||
| Palliative | 7 (87.5) | 19 (59.4) | |
| Adjuvant | 1 (12.5) | 5 (15.6) | |
| Curative | 0 (0) | 5 (15.6) | |
| Neoadjuvant | 0 (0) | 3 (9.4) | |
| Cycle of current chemotherapy, median (IQR) | 17 (4–28) | 4 (3–6) | .028 |
| Previous influenza vaccination | |||
| Previous year (2017–2018 vaccine) | 5 (62.5) | 7 (21.9) | .039 |
| Within 3 y | 5 (62.5) | 7 (21.9) | .039 |
| Seroprotection | |||
| H1N1 | 7 (87.5) | 20 (62.5) | .236 |
| H3N2 | 7 (87.5) | 18 (56.3) | .219 |
| No. of seroprotective strains, median (IQR) | 4 (2–4) | 2 (1–4) | .138 |
| Seroconversion | |||
| H1N1 | 5 (62.5) | 14 (43.8) | .442 |
| H3N2 | 3 (37.5) | 12 (37.5) | 1.000 |
| No. of seroconverted strains, median (IQR) | 3 (0–4) | 1 (0–4) | .366 |
| Characteristic . | Adequate CMI Response (n = 8) . | Inadequate CMI Response (n = 32) . | P Value . |
|---|---|---|---|
| Male sex | 0 (0) | 11 (34.4) | .080 |
| Age, y, mean ± SD | 67.5 ± 4.5 | 60.9 ± 9.6 | .070 |
| Age >60 y | 7 (87.5) | 17 (53.1) | .114 |
| ICI (vs cytotoxic chemotherapy) | 6 (75.0) | 5 (15.6) | .003 |
| ECOG performance status grade 0 | 6 (75.0) | 28 (87.5) | .580 |
| Comorbidity | |||
| Hypertension | 2 (25.0) | 6 (18.8) | .650 |
| Diabetes | 2 (25.0) | 6 (18.8) | .650 |
| Lung cancer | 6 (75.0) | 12 (37.5) | .110 |
| Purpose of chemotherapy | .420 | ||
| Palliative | 7 (87.5) | 19 (59.4) | |
| Adjuvant | 1 (12.5) | 5 (15.6) | |
| Curative | 0 (0) | 5 (15.6) | |
| Neoadjuvant | 0 (0) | 3 (9.4) | |
| Cycle of current chemotherapy, median (IQR) | 17 (4–28) | 4 (3–6) | .028 |
| Previous influenza vaccination | |||
| Previous year (2017–2018 vaccine) | 5 (62.5) | 7 (21.9) | .039 |
| Within 3 y | 5 (62.5) | 7 (21.9) | .039 |
| Seroprotection | |||
| H1N1 | 7 (87.5) | 20 (62.5) | .236 |
| H3N2 | 7 (87.5) | 18 (56.3) | .219 |
| No. of seroprotective strains, median (IQR) | 4 (2–4) | 2 (1–4) | .138 |
| Seroconversion | |||
| H1N1 | 5 (62.5) | 14 (43.8) | .442 |
| H3N2 | 3 (37.5) | 12 (37.5) | 1.000 |
| No. of seroconverted strains, median (IQR) | 3 (0–4) | 1 (0–4) | .366 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CMI, cell-mediated immune; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; IQR, interquartile range; SD, standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
